Ocular Therapeutix™ to be launched at UBS Virtual Ophthalmology Day 2024 By Investing.com
BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix (NASDAQ: ), Inc. (NASDAQ: OCUL, Ocular, the Company), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of new treatments for retinal diseases and other eye conditions, today announced that it will participate in UBS Virtual Opthalmology Day 2024:
UBS Virtual Ophthalmology Day 2024
Fireside Chat Date: Wednesday, October 2, 2024
Presentation Time: 3:00 PM ET
Speaker: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Visual
In addition to the fireside discussion, Ocular’s leadership will hold investor meetings at the conference. A live webcast of the fireside discussion can be accessed by visiting the investor section of the Company’s website at investor.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to advancing real-world vision through the development and commercialization of new treatments for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), an Ocular product candidate for retinal disease, is based on its innovative ELUTYX™ bioresorbable hydrogel-based technology. AXPAXLI is currently in phase 3 clinical trials for wet age-related macular degeneration (wet AMD (NASDAQ: )).
Ocular Pipeline also uses ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following eye surgery and ocular itching associated with allergic conjunctivitis, and its product candidate PAXTRAVA ™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn or X.
The Ocular Therapeutix logo and DEXTENZA ® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors and the media
Company Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
